Repatha (Evolocumab) Food & Supplement Interactions: What to Know Before You Inject

The direct answer

Evolocumab has no established pharmacokinetic interaction with any food or dietary supplement, because it is cleared by the same nonspecific proteolytic pathways that break down endogenous antibodies rather than by liver enzymes such as CYP3A4. This means grapefruit, St. John's wort, and similar CYP-modulating substances do not change evolocumab's blood levels or effect. It does not mean your diet and supplement stack are irrelevant: most people on evolocumab are also on a statin, and several common supplements (red yeast rice, berberine, high-dose niacin) act on the same lipid pathways or on statin metabolism in ways that can matter clinically. The current Repatha prescribing information does not list food or supplement contraindications; verify this against the version in effect at the time of reading, since labels are updated periodically.

How evolocumab works, and why that limits food interactions

Evolocumab is a fully human monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein the liver secretes that normally tags LDL receptors for degradation. By binding and neutralizing PCSK9, evolocumab allows more LDL receptors to stay on the surface of liver cells, which pulls more LDL cholesterol out of the bloodstream.

Oral cholesterol drugs, including statins, are absorbed through the gut and processed by CYP450 liver enzymes, which is why substances like grapefruit juice (a CYP3A4 inhibitor) can raise blood levels of atorvastatin or simvastatin. Evolocumab is injected subcutaneously, absorbed through the lymphatic system, and eventually broken down by general protein-degradation pathways rather than CYP450 enzymes. That is the structural reason it has such a clean interaction profile compared with oral lipid drugs.

Where the real risk sits: what patients stack around evolocumab

Because evolocumab is almost always prescribed alongside a maximally tolerated statin (and sometimes ezetimibe), the practical interaction question for most readers is not "does this supplement change my evolocumab level" but "does this supplement change what my statin is doing, or does it duplicate what my regimen is already trying to do."

Red yeast rice

Red yeast rice contains monacolin K, which is chemically identical to lovastatin. The FDA has taken enforcement action against red yeast rice products containing therapeutic-level monacolin K, on the basis that a product containing an approved drug's active ingredient is an unapproved drug. Independent testing of commercial red yeast rice supplements has repeatedly found wide, unlabeled variability in monacolin K content between brands and even between lots of the same brand; exact figures should be checked against the specific product and current testing data rather than assumed from any single old assay.

If you are on a statin plus evolocumab and you add red yeast rice, you are effectively adding an unmeasured second statin dose. That raises myopathy risk without a way to know how much extra exposure you are getting. Disclose any red yeast rice use to your prescriber, and do not substitute it for a prescribed statin.

Fish oil and omega-3 supplements

Prescription omega-3 formulations and over-the-counter fish oil are commonly taken alongside PCSK9 inhibitors. Fish oil's main lipid effect is on triglycerides, not LDL-C, so it works on a different fraction than evolocumab and there is no known pharmacokinetic interaction between the two.

Two points are worth flagging for a reader on evolocumab. First, high-dose fish oil (generally above 3 g/day of combined EPA and DHA) can have a mild antiplatelet effect and may matter if you are also on an anticoagulant or antiplatelet drug; discuss this with your prescriber rather than assuming it is trivial. Second, some DHA-containing formulations have been associated with a small rise in LDL-C in certain patients with high triglycerides. If your LDL-C moves up unexpectedly after starting fish oil while on evolocumab, ask whether the fish oil formulation, rather than treatment failure, could explain it.

Coenzyme Q10 (CoQ10)

Statins inhibit the mevalonate pathway, which also produces endogenous CoQ10, and statin users show measurably lower serum CoQ10 than non-users. Evolocumab does not touch this pathway, so there is no pharmacological reason to take CoQ10 specifically because of PCSK9 inhibitor use. If you are on evolocumab without a statin, statin-related CoQ10 depletion does not apply to you.

For the many evolocumab patients who are also on a statin, CoQ10 is sometimes used for suspected statin-associated muscle symptoms. The trial evidence on whether CoQ10 meaningfully reduces those symptoms is mixed and generally described as limited; some patients report subjective benefit without a clear effect on objective muscle enzyme markers. CoQ10 does not interfere with evolocumab's mechanism or its LDL-lowering effect, and typical studied doses (roughly 100-300 mg/day) do not require any evolocumab dose adjustment.

Niacin (vitamin B3)

High-dose niacin lowers LDL-C and raises HDL-C, and it was once a mainstay of lipid therapy. Large randomized trials in the statin era, including trials that added niacin to background statin therapy, did not show an incremental cardiovascular benefit from that addition, and documented increased risks such as myopathy, gastrointestinal events, and glucose elevation. Current cholesterol guidelines from major cardiology bodies now position niacin as a secondary option, generally considered only when statins, ezetimibe, and PCSK9 inhibitors are insufficient or not tolerated. (Verify current guideline wording and trial figures against the primary publications; specific trial names and exact effect sizes from the source material could not be independently confirmed for this draft and should be checked before republication.)

There is no known pharmacokinetic interaction between niacin and evolocumab. The concern is clinical redundancy: a patient already on a statin plus evolocumab has two potent, mechanistically distinct LDL-lowering therapies, and adding niacin for a small additional LDL reduction brings flushing, hepatotoxicity risk, and glucose effects without established added cardiovascular benefit in that setting.

Vitamin D

Vitamin D does not interact with evolocumab pharmacokinetically or pharmacodynamically, and standard supplementation doses (roughly 1,000-4,000 IU/day) are generally considered safe to take alongside it. Observational data have linked low vitamin D status with cardiovascular risk, but large randomized supplementation trials have not shown that correcting vitamin D level reduces cardiovascular events in an unselected population. Some smaller studies have explored whether correcting vitamin D deficiency lowers circulating PCSK9, but this is early, hypothesis-generating research, not a basis for adjusting evolocumab dosing or expecting a meaningful clinical effect.

Berberine

Berberine is a plant alkaloid marketed as a natural cholesterol-lowering agent, and trial data support a real LDL-C and triglyceride-lowering effect, working through a mechanism (upregulating hepatic LDL receptor expression) that is distinct from both statins and PCSK9 inhibitors. In principle this mechanism does not conflict with evolocumab, but no clinical trial has specifically tested the combination, so any expectation of additive benefit is theoretical rather than established.

The practical concern is that berberine inhibits CYP3A4 and CYP2D6. This does not affect evolocumab, but it can raise blood levels of co-prescribed statins metabolized by those enzymes, such as atorvastatin, lovastatin, or simvastatin, increasing myopathy risk. Berberine can also lower blood glucose and cause gastrointestinal upset at higher doses. Disclose berberine use to your prescriber before starting it or changing the dose.

Grapefruit and grapefruit juice

Grapefruit inhibits intestinal CYP3A4, which is a genuine concern for statins metabolized through that pathway, including atorvastatin, lovastatin, and simvastatin. Evolocumab is not metabolized by CYP3A4, so grapefruit has no direct effect on its levels or effect. If you take one of the CYP3A4-dependent statins alongside evolocumab, grapefruit can still raise statin exposure; this is a statin-grapefruit interaction, not an evolocumab-grapefruit interaction. Rosuvastatin and pravastatin are not CYP3A4 substrates, so this concern does not apply to those statins.

St. John's wort

St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein. It does not affect evolocumab directly, but it can reduce blood levels, and therefore effectiveness, of co-prescribed drugs that rely on those pathways, including certain statins, some anticoagulants, and some calcium channel blockers. If you take evolocumab as part of a broader cardiovascular regimen, tell your prescriber about any St. John's wort use, since the interaction risk sits with the other drugs in your regimen rather than with evolocumab itself.

Plant sterols and stanols

Sterol- and stanol-fortified foods and supplements, typically used around 2 g/day, lower LDL-C by competing with cholesterol for intestinal absorption, a mechanism unrelated to PCSK9 biology. They are generally considered safe to combine with evolocumab and may provide a modest additional LDL-C reduction on top of statin plus PCSK9 inhibitor therapy. No evolocumab dose adjustment is needed.

Diet patterns worth knowing about

Meal timing. Because evolocumab is injected rather than swallowed, meal composition and timing do not affect its absorption. There is no dietary restriction tied to injection days.

Ketogenic and very low-carbohydrate diets. In a subset of people, often lean individuals with low baseline triglycerides, very low-carbohydrate diets are associated with a marked rise in LDL-C, sometimes described as a "lean mass hyper-responder" pattern. If you start evolocumab and separately adopt a ketogenic diet, checking lipids some weeks after the diet change is a reasonable way to catch a paradoxical LDL-C rise early rather than assuming the medication has stopped working.

Alcohol. Moderate alcohol intake has no known interaction with evolocumab. Heavy alcohol use can raise triglycerides and stress the liver, which complicates overall lipid management, but this is a general cardiovascular and hepatic risk issue rather than an evolocumab-specific interaction.

What is established, what is plausible, and what is not established

Established: Evolocumab is cleared by non-hepatic proteolytic pathways and has no CYP450-mediated food or supplement interaction described in its FDA labeling. Grapefruit, St. John's wort, and similar CYP3A4-active substances do not change evolocumab exposure.

Plausible but not proven for this combination: That berberine plus evolocumab, or vitamin D correction plus evolocumab, produces meaningfully more LDL-C lowering than evolocumab alone. Mechanistic and small-study signals exist, but dedicated trials testing these combinations have not been done, as far as this review could confirm.

Not established: Any precise numeric effect size for red yeast rice content variability, niacin trial outcomes, or specific vitamin D-PCSK9 studies cited in older versions of this article could not be independently verified against a reliable identifier for this draft. Those figures should be checked against the primary literature before being republished with specific numbers attached.

A short, quotable summary

Evolocumab (Repatha), a PCSK9-inhibiting monoclonal antibody given by subcutaneous injection, is metabolized by general protein breakdown rather than liver CYP450 enzymes, so it has no established food-drug interaction and is not affected by grapefruit, St. John's wort, or similar compounds. Its FDA label does not list food or supplement contraindications as of the most recently reviewed version. The clinical risk that does exist comes from supplements that act on the statin most evolocumab patients also take, or that duplicate evolocumab's own LDL-lowering goal, which is why disclosure of every supplement to the prescribing clinician matters more than any evolocumab-specific food rule.

When to contact your care team

Contact your doctor if you experience unexplained muscle pain or weakness after beginning or adjusting any supplement, particularly red yeast rice or berberine; if your LDL-C does not decrease as anticipated at your next lab test or increases; if you initiate or discontinue drugs or supplements that influence liver metabolism, including berberine, St. John's wort, or high-dose niacin; or if your injection-site reactions worsen or become different. Get immediate medical attention if you notice symptoms of a serious allergic reaction (swelling of the face or throat, trouble breathing, extensive hives) or if you have severe, unexplained muscle pain accompanied by dark urine, which may indicate rhabdomyolysis. Provide your prescriber with a complete and up-to-date list of all supplements at every appointment for cholesterol management.

Decision framework: should you tell your prescriber before adding this supplement?

Use this quick sequence for any supplement you are considering while on evolocumab. It is a general decision aid, not a substitute for an individualized medical recommendation.

Step 1: Does the supplement affect LDL-C or triglycerides on its own?

• Yes (red yeast rice, berberine, niacin, plant sterols, fish oil) → go to Step 2.
• No, and it has no known effect on CYP450 statin metabolism → generally lower priority to flag, but still worth mentioning at your next visit.

Step 2: Does it also change statin blood levels (CYP3A4/CYP2D6 effect)?

• Yes (berberine, grapefruit with a CYP3A4-metabolized statin, St. John's wort) → disclose before starting; do not self-titrate your statin dose in response to how you feel.
• No → move to Step 3.

Step 3: Could it be mistaken for treatment failure or overtreatment on a lipid panel?

• Fish oil (possible LDL-C uptick), red yeast rice (unlabeled extra statin exposure), and ketogenic diets (possible large LDL-C rise) can all confuse the picture. If you plan to start one of these, ask your clinician when to recheck lipids so a change gets attributed correctly.
• If the supplement has no known lipid effect and no CYP interaction (most vitamin D use, standard-dose CoQ10), routine mention at your next visit is reasonable rather than an urgent call.

Step 4: Is there a symptom that changes the urgency?

• New muscle pain, weakness, or dark urine after adding any supplement → contact your care team promptly rather than waiting for a routine visit.
• No red-yeast-rice-scale change in monacolin exposure is ever guaranteed to be "the same dose as last time," even from the same brand, because content is not standardized the way a prescription statin is.

References

1. U.S. Food and Drug Administration. Repatha (evolocumab) prescribing information. Verify current revision at the time of reading.
2. U.S. Food and Drug Administration. Red yeast rice: dietary supplement products and ingredients information should be verified directly with the FDA.

Other claims in this article describing trial findings (statin-CoQ10 depletion, niacin outcome trials, omega-3 cardiovascular trials, vitamin D supplementation trials, berberine meta-analyses, plant sterol effects, and ketogenic diet LDL-C case reports) reflect commonly cited findings in the cardiometabolic literature, but the specific identifiers in the prior version of this page could not be verified as pointing to the correct source and were removed rather than carried forward incorrectly. A qualified reviewer should re-attach verified primary citations before publication.